Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

RIDGEFIELD, Conn., Sept. 20, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that data from 13 abstracts assessing the efficacy and safety of two of its investigational oncology compounds – afatinib and nintedanib – were selected for presentation at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria, September 28 – October 2, 2012.  These data represent Boehringer Ingelheim's commitment to further develop its oncology pipeline with the goal of bringing new treatment options to the oncology community.

Data will include results from Phase II and III studies of afatinib in various lung cancer treatment settings and patient groups as well as data on health-related quality of life and symptom control.  Data from Phase I studies of afatinib in advanced solid tumors will also be presented.  The nintedanib results are from Phase I studies in hepatocellular carcinoma and in combination with afatinib in advanced solid tumors.

"Boehringer Ingelheim is looking forward to sharing new results for our investigational oncology compounds with the global oncology community at ESMO," said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "This is an exciting time for Boehringer Ingelheim as we continue to explore the potential of our growing oncology pipeline."

 

Data for Boehringer Ingelheim Investigational Oncology Compounds at ESMO 2012TitleLead Study AuthorAbstract DetailsAfatinib*LUX-Lung 3: Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer

James Chih-Hsin Yang,

MD, PhD

ESMO Abstract # 1252P
Date: Saturday, September 29
Time: 13:00 – 14:00 PM CESTPhase II trial of afatinib as a third-line treatme
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... “We are honored to be named to ... CEO of Radiant Sage. “We are offering truly ground-breaking ... corelab market to a different level. We are ... efficiently and effectively manage the massive amounts of medical ... and read by trained physicians. Being recognized by technology ...
(Date:8/27/2014)... Reportbuyer.com has added a new market ... A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds graphene, ... to water treatment, but is graphene the only ... Graphene Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... Research and Markets has announced ... & Paper Industry Report 2014" report to their ... & Paper Industry Report 2014 is a professional and ... enzyme for pulp & paper industry. The ... definitions, classifications, applications and industry chain structure. The enzyme ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture Partners, ... investing in the development of seed and early-stage ... venture fund closed with more than $400 million ... $250 million subscription target by more than $150 ... shows the strength and potential of our approach ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... Anticipating a catastrophic increase in Alzheimer,s disease and related ... Plan for Alzheimer,s disease, a disease estimated to double ... a 10-year course of action with guiding principles, goals ... crisis.   Alzheimer,s will soon soar to ...
... 2011 GlobalCare Clinical Trials, Ltd, (GlobalCare) today ... selected clinical study visits at convenient locations – ... – for study patients to support phase I-IV ... and personalized medicine in all age groups. GlobalCare,s ...
... Inc. (NYSE Amex: PTN ) announced that it ... Stock Conference on Tuesday, March 15, 2011, at 12:00 p.m. ... Carlton Laguna Niguel in Dana Point, CA. ... Technologies, will provide an update on Palatin,s corporate and development ...
Cached Biology Technology:California Leaders Confront Alarming Rise in Alzheimer's Cases 2California Leaders Confront Alarming Rise in Alzheimer's Cases 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 2GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 4
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
(Date:8/27/2014)... based upon a proxy for impact have been identified ... approach to scientific research. , The researchers from the ... top 100 pathogens affecting humans and the top 100 ... will help governments across the continent plan for risks ... a result of climate change, and for biosecurity. , ...
(Date:8/27/2014)... news release is available in German . ... 1A is the most common inherited disease affecting the ... at the Max Planck Institute of Experimental Medicine and ... of Schwann cells is impaired in rats with the ... insulating layer known as myelin, which facilitates the rapid ...
Breaking Biology News(10 mins):Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... of researchers has shown that female kittens consume more food ... with entire littermates. This research was conducted at the WALTHAM ... Petcare brands such as WHISKAS and ROYAL CANIN. In ... consumed more food than their entire littermates for an 18 ...
... some strains of algae, when starved of nutrients, quickly build ... discovery lay dormant until people began to search in earnest ... 2000s, algal fuel production enjoyed a tremendous vogue, as scientists ... "pond scum" to oil. But a recent wave of bankruptcies ...
... October 2011, Christian Sonne, Senior Scientist at Aarhus University, defends ... University of Copenhagen. "The accumulated industrial chemicals cause diseases ... immediate deaths. On the other hand, the toxins damage the ... and not least their reproductive systems. However, the harm suffered ...
Cached Biology News:New research from WALTHAM demonstrates the importance of portion control for maintaining healthy body weight in neutered female kittens 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 3WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 4
... SDS and Non-ionic Detergent Removal ... detergent , Very selective, virtually no cross-reactivity ... centrifuge and discard pellet , Economical ... chromatography , Detergents can often interfere with ...
Extracti-Gel D Detergent Removing Gel...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
SDS-OutT SDS Precipitation Reagent...
Biology Products: